Prexasertib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer
Trial Timeline
Apr 10, 2018 → Oct 3, 2020
NCT ID
NCT03414047About Prexasertib
Prexasertib is a phase 2 stage product being developed by Eli Lilly for Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03414047. Target conditions include Ovarian Cancer.
What happened to similar drugs?
11 of 20 similar drugs in Ovarian Cancer were approved
Approved (11) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03414047 | Phase 2 | Completed |
| NCT02735980 | Phase 2 | Completed |
| NCT02514603 | Phase 1 | Completed |
| NCT01115790 | Phase 1 | Completed |
Competing Products
20 competing products in Ovarian Cancer